Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03213626
Title Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic Adenocarcinoma
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bert Howard O'Neil
Indications

pancreatic adenocarcinoma

Therapies

Cabozantinib + Erlotinib

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.